PALI revenueQ2 2026$500.0K
PALI revenue was $500.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Palisade Bio Inc. (PALI) financials
For the twelve months ended Jun 30, 2026, Palisade Bio Inc. reported $500.0K of revenue and -$31.94M of net income.
- Revenue, TTM
- $500.0K
- Net income, TTM
- -$31.94M
- Net margin
- -6388.2%
- Cash
- $125.17M
- P/S
- 393.85
- Market cap
- $196.9M
FY2016FY2025
FY2016FY2025
FY2016FY2024
PALI revenue and earnings growth
PALI net incomeQ2 2026-$10.57M
PALI net income was -$10.57M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.78M a year earlier. For the full fiscal 2025 it was -$16.78M, compared with -$14.44M in fiscal 2024.
PALI EPSQ2 2026-$0.05
PALI diluted EPS was -$0.05 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.30.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $300.0K | $0 | - | $13.5K | $15.4K | $260.0K | $260.0K | $16.2K |
| Research and development | $10.19M | $16.00M | $6.89M | $6.55M | $2.43M | $3.10M | $4.06M | $3.96M | $8.10M | $13.16M |
| Selling, general and admin | $7.86M | $5.80M | $6.20M | $8.76M | $9.31M | $6.20M | $4.59M | $4.56M | $5.47M | $7.50M |
| Operating income | -$18.06M | -$14.86M | -$13.07M | -$15.72M | -$41.85M | -$9.30M | -$8.63M | -$8.26M | -$13.31M | -$20.64M |
| Interest expense | $10.0K | $12.0K | $15.0K | $13.0K | $2.40M | $235.0K | $8.9K | $7.7K | $159.1K | $1.14M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $1.0K | - | - | - | $0 |
| Net income | -$16.78M | -$14.44M | -$12.30M | -$14.26M | -$26.62M | -$10.32M | -$8.35M | -$4.92M | -$15.67M | -$21.07M |
| EPS, basic | -$0.30 | -$10.19 | -$27.01 | -$247.95 | -$2144.25 | -$2790.00 | -$17100.00 | -$33930.00 | -$108000.00 | -$227700.00 |
| EPS, diluted | -$0.30 | -$10.19 | -$27.01 | -$247.95 | -$2546.10 | -$2790.00 | -$17100.00 | -$33930.00 | -$108000.00 | -$227700.00 |
| Diluted shares | 55.7M | 1.4M | 456,014 | 58,687.4 | 12,463.867 | 3,699.16 | 488.319 | 145.16 | 145.16 | 92.733 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $133.38M | $9.82M | $12.43M | $12.38M | $10.49M | $713.0K | $5.11M | $5.79M | $6.67M | $15.19M |
| Short-term investments | - | - | - | - | - | - | - | - | $5.00M | $5.00M |
| Receivables | $0 | $0 | - | $0 | $0 | $59.0K | $21.1K | $294.1K | $312.8K | $10.5K |
| Current assets | $134.22M | $10.49M | $13.33M | $14.73M | $11.51M | $896.0K | $5.65M | $6.51M | $12.45M | $20.90M |
| Total assets | $134.34M | $10.88M | $14.05M | $15.76M | $12.51M | $3.02M | $6.58M | $7.68M | $13.88M | $22.60M |
| Current liabilities | $4.64M | $3.24M | $2.59M | $3.01M | $2.50M | $8.08M | $1.22M | $1.05M | $1.51M | $7.33M |
| Short-term debt | - | - | - | - | $87.0K | $1.05M | - | - | - | $3.71M |
| Long-term debt | - | - | - | - | $0 | $94.0K | - | - | - | - |
| Total debt | - | - | - | - | $87.0K | $1.14M | - | - | - | - |
| Total liabilities | $4.96M | $3.39M | $2.74M | $3.28M | $5.15M | $10.12M | $1.46M | $1.63M | $5.37M | $11.27M |
| Shareholders' equity | $129.38M | $7.49M | $11.31M | $12.48M | $7.37M | -$16.60M | -$8.33M | $6.05M | $8.52M | $11.33M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.85M | -$12.19M | -$11.13M | -$13.36M | -$14.77M | -$4.77M | -$7.26M | -$7.69M | -$13.42M | -$15.62M |
| Capital expenditures | - | $0 | $4.0K | $10.0K | $0 | $6.0K | - | $1.7K | $11.4K | $98.1K |
| Free cash flow | - | -$12.19M | -$11.14M | -$13.37M | -$14.77M | -$4.77M | - | -$7.69M | -$13.43M | -$15.71M |
| Investing cash flow | - | $0 | -$4.0K | -$10.0K | -$54.0K | -$6.0K | - | $5.00M | -$94.0K | $2.36M |
| Financing cash flow | $134.44M | $9.58M | $11.19M | $15.26M | $24.61M | $1.89M | $6.59M | $1.81M | $4.99M | $23.74M |
| Stock-based compensation | $3.96M | $652.0K | $624.0K | $1.03M | $1.89M | $2.01M | $880.8K | $634.1K | $1.77M | $3.45M |
| Depreciation and amortization | - | - | - | $3.0K | $2.0K | $3.0K | $143.9K | $185.8K | $289.2K | $337.5K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | -100.0% | - | - | - | -12.2% | -94.1% | 0.0% | 1500.4% | 56.0% |
| Operating margin | - | - | -4356.7% | - | - | -68764.8% | -56071.8% | -3176.7% | -5118.1% | -127027.2% |
| Net margin | - | - | -4100.0% | - | - | -76346.2% | -54252.6% | -1894.1% | -6025.4% | -129721.8% |
| Free cash flow margin | - | - | -3712.3% | - | - | -35310.7% | - | -2959.3% | -5164.4% | -96726.6% |
| Return on equity | -13.0% | -192.7% | -108.7% | -114.3% | -361.4% | - | - | -81.4% | -184.0% | -186.0% |
| Return on assets | -12.5% | -132.7% | -87.5% | -90.5% | -212.7% | -341.9% | -126.8% | -64.1% | -112.8% | -93.2% |
| Current ratio | 28.95 | 3.24 | 5.15 | 4.89 | 4.61 | 0.11 | 4.61 | 6.19 | 8.22 | 2.85 |
| Debt to equity | - | - | - | - | 0.01 | - | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $50.0K | $0 |
| Research and development | $6.00M | $6.00M | $6.17M | $1.39M | $1.68M | $950.0K | $0 | $16.00M | $2.63M | $2.21M | $362.0K | $2.10M |
| Selling, general and admin | $4.80M | $4.35M | $3.81M | $1.53M | $1.17M | $1.36M | $1.30M | $1.46M | $1.58M | $1.46M | $1.56M | $1.67M |
| Operating income | -$11.70M | -$10.75M | -$9.98M | -$2.92M | -$2.84M | -$2.31M | -$3.38M | -$3.59M | -$4.21M | -$3.67M | -$3.15M | -$3.78M |
| Interest expense | $0 | $1.0K | $2.0K | $5.0K | $2.0K | $1.0K | $3.0K | $6.0K | $2.0K | $1.0K | $4.0K | $8.0K |
| Net income | -$10.57M | -$9.60M | -$8.90M | -$2.87M | -$2.78M | -$2.23M | -$3.34M | -$3.49M | -$4.08M | -$3.53M | -$2.97M | -$3.60M |
| EPS, basic | -$0.05 | -$0.05 | - | -$0.38 | -$0.58 | -$0.47 | - | -$2.32 | -$3.32 | -$4.59 | - | -$7.38 |
| EPS, diluted | -$0.05 | -$0.05 | - | -$0.38 | -$0.58 | -$0.47 | - | -$2.32 | -$3.32 | -$4.59 | - | -$7.38 |
| Diluted shares | 211.4M | 209.7M | - | 7.5M | 4.8M | 4.8M | - | 1.5M | 1.2M | 768,137 | - | 489,624 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $125.17M | $132.63M | $133.38M | $5.23M | $5.42M | $7.23M | $9.82M | $8.04M | $11.35M | $11.28M | $12.43M | $15.31M |
| Receivables | $500.0K | - | $0 | - | $0 | - | $0 | - | - | - | - | - |
| Current assets | $127.26M | $133.24M | $134.22M | $6.83M | $6.45M | $7.89M | $10.49M | $8.87M | $12.31M | $12.01M | $13.33M | $16.27M |
| Total assets | $127.31M | $133.31M | $134.34M | $6.97M | $6.67M | $8.19M | $10.88M | $9.34M | $12.87M | $12.65M | $14.05M | $17.07M |
| Current liabilities | $5.25M | $5.62M | $4.64M | $3.48M | $3.97M | $2.78M | $3.24M | $2.68M | $2.84M | $2.47M | $2.59M | $2.65M |
| Total liabilities | $5.57M | $5.95M | $4.96M | $3.76M | $4.05M | $2.86M | $3.39M | $2.73M | $2.92M | $2.59M | $2.74M | $2.98M |
| Shareholders' equity | $121.75M | $127.36M | $129.38M | $3.21M | $2.62M | $5.33M | $7.49M | $6.61M | $9.95M | $10.06M | $11.31M | $14.08M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.60M | -$3.89M | -$3.14M | -$3.55M | -$1.82M | -$2.33M | -$2.38M | -$3.13M | -$3.50M | -$3.18M | -$2.75M | -$2.66M |
| Capital expenditures | - | - | - | - | - | - | $0 | $0 | - | - | $0 | $0 |
| Free cash flow | - | - | - | - | - | - | -$2.38M | -$3.13M | - | - | -$2.75M | -$2.66M |
| Investing cash flow | - | - | - | - | - | - | $0 | $0 | - | - | $0 | $0 |
| Financing cash flow | $147.0K | $3.13M | $131.33M | $3.36M | $4.0K | -$258.0K | $4.16M | -$180.0K | $3.58M | $2.02M | -$134.0K | $1.57M |
| Stock-based compensation | $4.79M | $4.30M | $3.73M | $90.0K | $69.0K | $69.0K | $77.0K | $95.0K | $362.0K | $118.0K | $185.0K | $202.0K |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | - | - | $1.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -100.0% | - | - | -100.0% | - | - |
| Operating margin | -2339.6% | - | - | - | - | - | - | - | - | - | -6308.0% | - |
| Net margin | -2114.8% | - | - | - | - | - | - | - | - | - | -5942.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - | -5492.0% | - |
| Current ratio | 24.26 | 23.71 | 28.95 | 1.96 | 1.62 | 2.84 | 3.24 | 3.31 | 4.34 | 4.87 | 5.15 | 6.14 |
Source: XBRL data Palisade Bio Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-13, first reported Mar 23, 2017; 1-for-20, first reported Aug 14, 2019; 1-for-6, first reported May 14, 2021; 1-for-50, first reported Mar 22, 2023; 1-for-15, first reported May 13, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PALI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PALI | $500.0K | - | -$31.94M | -6388.2% | $196.9M |
| CABA | - | - | -$189.50M | - | $221.3M |
| TIL | $8.97M | +2.5% | -$30.28M | -337.7% | $46.3M |
| INMB | $50.0K | +257.1% | -$45.93M | -91866.0% | $35.0M |
| ACET | $5.01M | -20.8% | -$91.00M | -1817.7% | $28.6M |
| PASG | - | - | -$36.11M | - | $12.8M |
PALI FAQ
5 questionsWhat is PALI revenue?
Palisade Bio Inc. (PALI) reported $500.0K of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $0.Is PALI profitable?
No. Palisade Bio Inc. reported a net loss of $31.94M for the twelve months ended Jun 30, 2026.How much cash and debt does PALI have?
Palisade Bio Inc. reported $125.17M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did PALI last report financial results?
The latest statements here come from Palisade Bio Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this PALI financial data come from?
Quantisnow builds these statements from the structured XBRL data Palisade Bio Inc. files with the SEC. It is provided for information only and is not investment advice.